• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于载体的 shRNA-mdr1 在体外和体内逆转多药耐药性

Reversal of multi-drug resistance by vector-based-shRNA-mdr1 in vitro and in vivo.

作者信息

Lu Shi, Huang Qi, Wang Zehua, Song Yinfeng, Wang Lijun

机构信息

Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

出版信息

J Huazhong Univ Sci Technolog Med Sci. 2009 Oct;29(5):620-4. doi: 10.1007/s11596-009-0517-2. Epub 2009 Oct 11.

DOI:10.1007/s11596-009-0517-2
PMID:19821097
Abstract

In order to investigate the effects of vector-based hairpin small interference RNA (shRNA) on the reversal of multi-drug resistance (mdr) of A2780/Taxol cells, a novel vector pEGFP-H1/mdr1 containing mdr1-shRNA targeting at position 2943-2963 of mdr1 was designed and synthesized. Subsequently, A2780/Taxol cells were transfected with pEGFP-H1/mdr1, and the expression of mdr1 mRNA and P-gp was detected by using RT-PCR and Western blot respectively. MTT was used to measure the 50% inhibition concentration (IC(50)) of Taxol to A2780/Taxol cells. The results showed that at the 24th and 48th h after transfection, the expression of mdr1 mRNA was decreased to (52.1+/-1.0)% and (0.01+/-1.7)%, and that of P-gp decreased to (88.3+/-2.1)% and 0%, respectively. At the 48th h after transfection, the relative reversal rate of A2780/Taxol cells to Taxol was 69.54%. In vivo, the nude mice xenografts were injected with pEGFP-H1/mdr1, and then administrated Taxol. The tumor volume in pEGFP-H1/mdr1-transfected group was significantly reduced as compared with that in blank control group or pEGFP-H1-transfected group (807.20+/-103.16 vs 1563.78+/-210.54 or 1480.78+/-241.24 mm(3), both P<0.01). These results suggested that transfection of pEGFP-H1/mdr1 could efficiently down-regulate the expression of mdr1 mRNA and P-gp in A2780/Taxol cells, and effectively restore the sensitivity of A2780/Taxol cells to Taxol both in vitro and in vivo.

摘要

为研究基于载体的发夹状小干扰RNA(shRNA)对A2780/Taxol细胞多药耐药(mdr)逆转的影响,设计并合成了一种新型载体pEGFP-H1/mdr1,其含有靶向mdr1基因2943 - 2963位的mdr1-shRNA。随后,用pEGFP-H1/mdr1转染A2780/Taxol细胞,分别采用RT-PCR和Western blot检测mdr1 mRNA和P-糖蛋白(P-gp)的表达。用MTT法测定紫杉醇对A2780/Taxol细胞的半数抑制浓度(IC50)。结果显示,转染后第24小时和48小时,mdr1 mRNA表达分别降至(52.1±1.0)%和(0.01±1.7)%,P-gp表达分别降至(88.3±2.1)%和0%。转染后第48小时,A2780/Taxol细胞对紫杉醇的相对逆转率为69.54%。在体内,对裸鼠移植瘤注射pEGFP-H1/mdr1,然后给予紫杉醇。与空白对照组或pEGFP-H1转染组相比,pEGFP-H1/mdr1转染组的肿瘤体积显著减小(807.20±103.16 vs 1563.78±210.54或1480.78±241.24 mm3,均P<0.01)。这些结果表明,转染pEGFP-H1/mdr1可有效下调A2780/Taxol细胞中mdr1 mRNA和P-gp的表达,并在体外和体内有效恢复A2780/Taxol细胞对紫杉醇的敏感性。

相似文献

1
Reversal of multi-drug resistance by vector-based-shRNA-mdr1 in vitro and in vivo.基于载体的 shRNA-mdr1 在体外和体内逆转多药耐药性
J Huazhong Univ Sci Technolog Med Sci. 2009 Oct;29(5):620-4. doi: 10.1007/s11596-009-0517-2. Epub 2009 Oct 11.
2
[Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].[肝素结合表皮生长因子样生长因子抑制剂对卵巢癌紫杉醇耐药性的逆转]
Zhonghua Fu Chan Ke Za Zhi. 2017 Feb 25;52(2):110-115. doi: 10.3760/cma.j.issn.0529-567X.2017.02.008.
3
[Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel].[MDR1和MDR3基因沉默对A2780/紫杉醇细胞紫杉醇耐药性的逆转作用]
Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
4
Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells.靶向MDR1基因的壳聚糖/pshRNA质粒纳米颗粒逆转卵巢癌细胞对紫杉醇的耐药性。
J Huazhong Univ Sci Technolog Med Sci. 2009 Apr;29(2):239-42. doi: 10.1007/s11596-009-0221-2. Epub 2009 Apr 28.
5
Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro.pSUPER-shRNA-mdr1在体内外逆转多药耐药性
World J Gastroenterol. 2009 Jan 28;15(4):431-40. doi: 10.3748/wjg.15.431.
6
Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo.基于载体的RNA干扰在体外和体内逆转MDR1/P-糖蛋白介导的多药耐药性
Cancer Biol Ther. 2006 Jan;5(1):39-47. doi: 10.4161/cbt.5.1.2236. Epub 2006 Jan 12.
7
Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.紫杉醇诱导卵巢癌细胞系多药耐药的机制分析
Asian Pac J Cancer Prev. 2013;14(9):4983-8. doi: 10.7314/apjcp.2013.14.9.4983.
8
Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.通过短发夹RNA下调基因MDR1以逆转卵巢癌A2780细胞的多药耐药性。
J Cancer Res Ther. 2012 Apr-Jun;8(2):226-31. doi: 10.4103/0973-1482.98975.
9
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells.磁性 Fe3O4 纳米粒子共载柔红霉素和 MDR1 shRNA 表达载体逆转白血病细胞多药耐药。
Int J Nanomedicine. 2010 Aug 9;5:437-44. doi: 10.2147/ijn.s10083.
10
MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.多药耐药基因1和多药耐药基因3与卵巢癌细胞对顺铂的耐药性
J Huazhong Univ Sci Technolog Med Sci. 2007 Dec;27(6):721-4. doi: 10.1007/s11596-007-0627-7.

引用本文的文献

1
Cell Migration Related to MDR-Another Impediment to Effective Chemotherapy?细胞迁移与多药耐药性——化疗效果的又一障碍?
Molecules. 2018 Feb 5;23(2):331. doi: 10.3390/molecules23020331.

本文引用的文献

1
Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells.靶向MDR1基因的壳聚糖/pshRNA质粒纳米颗粒逆转卵巢癌细胞对紫杉醇的耐药性。
J Huazhong Univ Sci Technolog Med Sci. 2009 Apr;29(2):239-42. doi: 10.1007/s11596-009-0221-2. Epub 2009 Apr 28.
2
Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro.pSUPER-shRNA-mdr1在体内外逆转多药耐药性
World J Gastroenterol. 2009 Jan 28;15(4):431-40. doi: 10.3748/wjg.15.431.
3
Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA.
通过喷射注射编码抗MDR1短发夹RNA的质粒DNA实现多药耐药表型在体内的完全逆转。
Mol Ther. 2008 Jan;16(1):178-86. doi: 10.1038/sj.mt.6300304. Epub 2007 Sep 18.
4
Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter.使用由多药耐药基因1(MDR1)启动子指导的腺病毒介导的胞嘧啶脱氨酶基因和尿嘧啶磷酸核糖转移酶基因转移进行卵巢癌的基因治疗。
Cancer Biol Ther. 2007 Mar;6(3):397-404. doi: 10.4161/cbt.6.3.3754. Epub 2007 Mar 28.
5
MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance.多药耐药蛋白1/ P-糖蛋白(ABCB1)作为RNA干扰介导的多药耐药逆转靶点。
Curr Drug Targets. 2006 Jul;7(7):813-21. doi: 10.2174/138945006777709566.
6
Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux.P-糖蛋白介导的药物外排机制研究的最新进展。
J Membr Biol. 2005 Aug;206(3):173-85. doi: 10.1007/s00232-005-0792-1.
7
Therapeutic potential of RNA interference.RNA干扰的治疗潜力。
N Engl J Med. 2004 Oct 21;351(17):1772-7. doi: 10.1056/NEJMra045004.
8
Unlocking the potential of the human genome with RNA interference.利用RNA干扰释放人类基因组的潜能。
Nature. 2004 Sep 16;431(7006):371-8. doi: 10.1038/nature02870.
9
Asymmetry in the assembly of the RNAi enzyme complex.RNA干扰酶复合体组装中的不对称性。
Cell. 2003 Oct 17;115(2):199-208. doi: 10.1016/s0092-8674(03)00759-1.
10
Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.多药耐药相关蛋白1硫代磷酸酯反义寡脱氧核苷酸对多药耐药人肿瘤细胞系及异种移植瘤的作用
Anticancer Res. 2003 May-Jun;23(3B):2681-90.